drugset / Trial / NCT03117335
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Phase 3
Completed
560 enrolled
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to improve progression free survival (PFS) , disease control rate(DCR) , objective response rate(ORR) and Overall survival (OS) compared with chemotherapy alone, and evaluate the efficacy and safety of Sulijia.
Timeline
- Start
- 2011-11-10
- Primary completion
- 2016-11-14
- Completion
- 2017-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sulijia | Unknown | 7.5 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |